Which has better valuation and earnings, NRC or OPRX?

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio National Research $137.39M 3.67 $11.60M $0.25 88.66 OptimizeRx $109.43M 1.33 $5.13M $0.23 33.71

Does the media favor NRC or OPRX?

In the previous week, OptimizeRx had 1 more articles in the media than National Research. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat OptimizeRx's score of 0.93 indicating that National Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EVH or OPRX?

In the previous week, Evolent Health and Evolent Health both had 3 articles in the media. OptimizeRx's average media sentiment score of 0.93 beat Evolent Health's score of 0.93 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OPRX or AMWL?

In the previous week, OptimizeRx had 1 more articles in the media than American Well. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for American Well. OptimizeRx's average media sentiment score of 0.93 beat American Well's score of 0.88 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive American Well 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HCAT or OPRX?

In the previous week, OptimizeRx had 1 more articles in the media than Health Catalyst. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Health Catalyst. OptimizeRx's average media sentiment score of 0.93 beat Health Catalyst's score of 0.91 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OPRX or DH?

In the previous week, OptimizeRx and OptimizeRx both had 3 articles in the media. OptimizeRx's average media sentiment score of 0.93 beat Definitive Healthcare's score of 0.82 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definitive Healthcare 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OptimizeRx (OPRX) Competitors

$7.75 +0.46 (+6.36%)

As of 01:03 PM Eastern

Compare

OPRX vs. NRC, EVH, AMWL, HCAT, and DH

Should you buy OptimizeRx stock or one of its competitors? OptimizeRx's main competitors and comparable companies include National Research (NRC), Evolent Health (EVH), American Well (AMWL), Health Catalyst (HCAT), and Definitive Healthcare (DH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does OptimizeRx compare to National Research?

National Research (NASDAQ:NRC) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

National Research has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

47.3% of National Research shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 7.5% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

OptimizeRx has a net margin of 4.66% compared to National Research's net margin of 4.18%. National Research's return on equity of 164.26% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
OptimizeRx	4.66%	9.44%	7.11%

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.67	$11.60M	$0.25	88.66
OptimizeRx	$109.43M	1.33	$5.13M	$0.23	33.71

In the previous week, OptimizeRx had 1 more articles in the media than National Research. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat OptimizeRx's score of 0.93 indicating that National Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

National Research currently has a consensus price target of $26.00, suggesting a potential upside of 17.30%. OptimizeRx has a consensus price target of $11.43, suggesting a potential upside of 47.39%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

National Research beats OptimizeRx on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Evolent Health?

Evolent Health (NYSE:EVH) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Evolent Health presently has a consensus target price of $5.96, suggesting a potential upside of 44.94%. OptimizeRx has a consensus target price of $11.43, suggesting a potential upside of 47.39%. Given OptimizeRx's higher possible upside, analysts clearly believe OptimizeRx is more favorable than Evolent Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

76.5% of OptimizeRx shares are held by institutional investors. 1.5% of Evolent Health shares are held by company insiders. Comparatively, 7.5% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OptimizeRx has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.25	-$534.51M	-$4.57	N/A
OptimizeRx	$109.43M	1.33	$5.13M	$0.23	33.71

In the previous week, Evolent Health and Evolent Health both had 3 articles in the media. OptimizeRx's average media sentiment score of 0.93 beat Evolent Health's score of 0.93 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolent Health has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

OptimizeRx has a net margin of 4.66% compared to Evolent Health's net margin of -24.08%. OptimizeRx's return on equity of 9.44% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
OptimizeRx	4.66%	9.44%	7.11%

Summary

OptimizeRx beats Evolent Health on 12 of the 15 factors compared between the two stocks.

How does OptimizeRx compare to American Well?

OptimizeRx (NASDAQ:OPRX) and American Well (NYSE:AMWL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

OptimizeRx has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, American Well has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

In the previous week, OptimizeRx had 1 more articles in the media than American Well. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for American Well. OptimizeRx's average media sentiment score of 0.93 beat American Well's score of 0.88 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
American Well	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has a net margin of 4.66% compared to American Well's net margin of -35.75%. OptimizeRx's return on equity of 9.44% beat American Well's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
American Well	-35.75%	-30.12%	-22.30%

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 56.1% of American Well shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 12.8% of American Well shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OptimizeRx presently has a consensus target price of $11.43, suggesting a potential upside of 47.39%. American Well has a consensus target price of $9.50, suggesting a potential downside of 30.43%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
American Well	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OptimizeRx has higher earnings, but lower revenue than American Well. American Well is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.33	$5.13M	$0.23	33.71
American Well	$249.32M	0.91	-$95.70M	-$4.77	N/A

Summary

OptimizeRx beats American Well on 13 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Health Catalyst?

Health Catalyst (NASDAQ:HCAT) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Health Catalyst presently has a consensus target price of $2.45, suggesting a potential upside of 37.25%. OptimizeRx has a consensus target price of $11.43, suggesting a potential upside of 47.39%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, OptimizeRx had 1 more articles in the media than Health Catalyst. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Health Catalyst. OptimizeRx's average media sentiment score of 0.93 beat Health Catalyst's score of 0.91 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.43	-$177.97M	-$3.68	N/A
OptimizeRx	$109.43M	1.33	$5.13M	$0.23	33.71

OptimizeRx has a net margin of 4.66% compared to Health Catalyst's net margin of -90.61%. OptimizeRx's return on equity of 9.44% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
OptimizeRx	4.66%	9.44%	7.11%

85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 7.5% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Health Catalyst has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

OptimizeRx beats Health Catalyst on 12 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Definitive Healthcare?

OptimizeRx (NASDAQ:OPRX) and Definitive Healthcare (NASDAQ:DH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

OptimizeRx has a net margin of 4.66% compared to Definitive Healthcare's net margin of -72.28%. OptimizeRx's return on equity of 9.44% beat Definitive Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
Definitive Healthcare	-72.28%	3.55%	1.63%

OptimizeRx has higher earnings, but lower revenue than Definitive Healthcare. Definitive Healthcare is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.33	$5.13M	$0.23	33.71
Definitive Healthcare	$241.52M	0.46	-$138.93M	-$1.60	N/A

OptimizeRx has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Definitive Healthcare has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are held by institutional investors. 7.5% of OptimizeRx shares are held by company insiders. Comparatively, 17.1% of Definitive Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, OptimizeRx and OptimizeRx both had 3 articles in the media. OptimizeRx's average media sentiment score of 0.93 beat Definitive Healthcare's score of 0.82 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definitive Healthcare	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx presently has a consensus target price of $11.43, suggesting a potential upside of 47.39%. Definitive Healthcare has a consensus target price of $1.47, suggesting a potential upside of 42.17%. Given OptimizeRx's stronger consensus rating and higher probable upside, equities analysts clearly believe OptimizeRx is more favorable than Definitive Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Definitive Healthcare	3 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	1.90

Summary

OptimizeRx beats Definitive Healthcare on 11 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPRX vs. The Competition

Export

Metric	OptimizeRx	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$146.76M	$1.71B	$7.21B	$12.79B
Dividend Yield	N/A	4.70%	2.57%	11.71%
P/E Ratio	33.87	20.80	274.47	25.54
Price / Sales	1.33	92.61	636.76	89.10
Price / Cash	7.41	31.57	28.42	34.96
Price / Book	1.13	6.20	10.45	6.27
Net Income	$5.13M	-$18.66M	$3.49B	$358.19M
7 Day Performance	-1.47%	-0.07%	-2.00%	-1.14%
1 Month Performance	-11.08%	2.54%	0.59%	-2.41%
1 Year Performance	-55.26%	-12.99%	24.81%	8.87%

OptimizeRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPRX OptimizeRx	3.81 of 5 stars	$7.75 +6.4%	$11.43 +47.4%	-57.9%	$146.76M	$109.43M	33.87	100	News Coverage
NRC National Research	2.5642 of 5 stars	$20.72 -2.5%	$26.00 +25.5%	+31.9%	$471.38M	$137.39M	82.88	490	News Coverage
EVH Evolent Health	3.1529 of 5 stars	$4.12 -1.3%	$5.96 +44.9%	-54.0%	$465.24M	$1.88B	N/A	4,200
AMWL American Well	2.2744 of 5 stars	$12.99 +1.5%	$9.50 -26.8%	+97.1%	$214.90M	$249.32M	N/A	1,040
HCAT Health Catalyst	3.1898 of 5 stars	$1.75 +0.9%	$2.45 +40.4%	-45.7%	$131.33M	$311.14M	N/A	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPRX) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Competitors

OPRX vs. NRC, EVH, AMWL, HCAT, and DH

How does OptimizeRx compare to National Research?

Summary

How does OptimizeRx compare to Evolent Health?

Summary

How does OptimizeRx compare to American Well?

Summary

How does OptimizeRx compare to Health Catalyst?

Summary

How does OptimizeRx compare to Definitive Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OptimizeRx (OPRX) Competitors

OPRX vs. NRC, EVH, AMWL, HCAT, and DH

How does OptimizeRx compare to National Research?

Which has more volatility and risk, NRC or OPRX?

Do insiders and institutionals hold more shares of NRC or OPRX?

Is NRC or OPRX more profitable?

Which has better valuation and earnings, NRC or OPRX?

Does the media favor NRC or OPRX?

Do analysts rate NRC or OPRX?

Summary

How does OptimizeRx compare to Evolent Health?

Do analysts rate EVH or OPRX?

Do institutionals & insiders have more ownership in EVH or OPRX?

Which has stronger valuation and earnings, EVH or OPRX?

Does the media prefer EVH or OPRX?

Which has more risk & volatility, EVH or OPRX?

Is EVH or OPRX more profitable?

Summary

How does OptimizeRx compare to American Well?

Which has more volatility & risk, OPRX or AMWL?

Does the media refer more to OPRX or AMWL?

Is OPRX or AMWL more profitable?

Do insiders and institutionals have more ownership in OPRX or AMWL?

Do analysts rate OPRX or AMWL?

Which has higher earnings & valuation, OPRX or AMWL?

Summary

How does OptimizeRx compare to Health Catalyst?

Do analysts prefer HCAT or OPRX?

Does the media favor HCAT or OPRX?

Which has stronger earnings and valuation, HCAT or OPRX?

Is HCAT or OPRX more profitable?

Do insiders and institutionals hold more shares of HCAT or OPRX?

Which has more volatility & risk, HCAT or OPRX?

Summary

How does OptimizeRx compare to Definitive Healthcare?

Is OPRX or DH more profitable?

Which has preferable earnings and valuation, OPRX or DH?

Which has more risk & volatility, OPRX or DH?

Do insiders & institutionals hold more shares of OPRX or DH?

Does the media prefer OPRX or DH?

Do analysts prefer OPRX or DH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools